Compare 8x8 Inc (EGHT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs ResMed Inc. — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while ResMed Inc. trades at $231.16 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 102.2× 8x8 Inc's market cap, and ResMed Inc. pays a 1.16% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and ResMed Inc. for 51 Days on average.
| EGHT | RMD | |
|---|---|---|
Market Cap | $311.98M | $31.89B |
Volume | 1,639,086 | 618,314 |
Sector | Technology | Health |
52-Week High | $2.76 | $277.88 |
52-Week Low | $1.59 | $182.82 |
Typical Hold Time | 16 Days | 51 Days |
Enterprise Value | $578.90M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.15, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21M in 2025 but shows improving trends with revenue growth to $745M and a projected net profit of $5M in 2026. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus is a Buy with a $19.77 price target, suggesting significant upside potential from current levels.
The outlook is cautiously optimistic, with earnings beats and projected profitability offering opportunity, but high debt and thin margins pose risks. Investor sentiment is mixed amid valuation concerns, yet institutional interest and strategic partnerships support a positive long-term view if execution improves.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
